ZA200300377B - Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same. - Google Patents
Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same. Download PDFInfo
- Publication number
- ZA200300377B ZA200300377B ZA200300377A ZA200300377A ZA200300377B ZA 200300377 B ZA200300377 B ZA 200300377B ZA 200300377 A ZA200300377 A ZA 200300377A ZA 200300377 A ZA200300377 A ZA 200300377A ZA 200300377 B ZA200300377 B ZA 200300377B
- Authority
- ZA
- South Africa
- Prior art keywords
- bacteria
- applying
- act
- article
- nitric oxide
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 260
- 238000004519 manufacturing process Methods 0.000 title claims description 29
- 241001453382 Nitrosomonadales Species 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 title claims description 18
- 239000002243 precursor Substances 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 28
- 241000894006 Bacteria Species 0.000 claims description 156
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 68
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 66
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 65
- 239000004202 carbamide Substances 0.000 claims description 40
- 229910002651 NO3 Inorganic materials 0.000 claims description 38
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 37
- 229910021529 ammonia Inorganic materials 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 238000003287 bathing Methods 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 15
- 150000003863 ammonium salts Chemical class 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 241000605122 Nitrosomonas Species 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 241001495394 Nitrosospira Species 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 241000192147 Nitrosococcus Species 0.000 claims description 6
- 241000192123 Nitrosovibrio Species 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 241001116389 Aloe Species 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000011575 calcium Chemical class 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- 229910052570 clay Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000011777 magnesium Chemical class 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 239000011733 molybdenum Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000006174 pH buffer Substances 0.000 claims description 3
- 210000003899 penis Anatomy 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000010452 phosphate Chemical class 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000011591 potassium Chemical class 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- 239000011734 sodium Chemical class 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- -1 stick Substances 0.000 claims description 3
- 239000011573 trace mineral Chemical class 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 229910052751 metal Chemical class 0.000 claims description 2
- 239000002184 metal Chemical class 0.000 claims description 2
- 159000000014 iron salts Chemical class 0.000 claims 6
- 230000000386 athletic effect Effects 0.000 claims 3
- 210000003608 fece Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 206010048629 Wound secretion Diseases 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 2
- 210000003756 cervix mucus Anatomy 0.000 claims 2
- 230000002175 menstrual effect Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 210000003103 bodily secretion Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002781 deodorant agent Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 210000003746 feather Anatomy 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 239000010871 livestock manure Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 210000004761 scalp Anatomy 0.000 description 14
- 208000008454 Hyperhidrosis Diseases 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 230000035900 sweating Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000002840 nitric oxide donor Substances 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 8
- 230000001651 autotrophic effect Effects 0.000 description 8
- 208000019622 heart disease Diseases 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000605159 Nitrobacter Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 239000003570 air Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008821 health effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010047141 Vasodilatation Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000005554 pickling Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 244000005714 skin microbiome Species 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 241000192146 Nitrosococcus oceani Species 0.000 description 2
- 241000605121 Nitrosomonas europaea Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- QEIQEORTEYHSJH-UHFFFAOYSA-N Armin Natural products C1=CC(=O)OC2=C(O)C(OCC(CCO)C)=CC=C21 QEIQEORTEYHSJH-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 235000019542 Cured Meats Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 241000191953 Kocuria varians Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 208000034817 Waterborne disease Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- DCDCJJSNSWFVBG-UHFFFAOYSA-N azanylidyneoxidanium;iron Chemical group [Fe].[O+]#N.[O+]#N DCDCJJSNSWFVBG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 230000008599 nitrosative stress Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
- D06M16/003—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic with enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/70—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor
- A23L13/72—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor using additives, e.g. by injection of solutions
- A23L13/74—Tenderised or flavoured meat pieces; Macerating or marinating solutions specially adapted therefor using additives, e.g. by injection of solutions using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P3/00—Preparation of elements or inorganic compounds except carbon dioxide
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Textile Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Materials Engineering (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22459800P | 2000-08-11 | 2000-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300377B true ZA200300377B (en) | 2004-01-22 |
Family
ID=22841351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300377A ZA200300377B (en) | 2000-08-11 | 2003-01-14 | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7820420B2 (el) |
| EP (1) | EP1313574B1 (el) |
| JP (1) | JP2004506028A (el) |
| KR (1) | KR20030065463A (el) |
| CN (1) | CN1267212C (el) |
| AP (1) | AP1682A (el) |
| AT (1) | ATE412475T1 (el) |
| AU (2) | AU2001284849B2 (el) |
| BR (1) | BRPI0113085B1 (el) |
| CA (1) | CA2414941C (el) |
| DE (1) | DE60136366D1 (el) |
| EA (1) | EA005649B1 (el) |
| IL (2) | IL153956A0 (el) |
| MX (1) | MXPA03001280A (el) |
| OA (1) | OA12585A (el) |
| WO (1) | WO2002013982A1 (el) |
| ZA (1) | ZA200300377B (el) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308438C (zh) * | 2002-01-11 | 2007-04-04 | 大卫·R·怀特洛克 | 含有氨氧化细菌的化合物以及使用的方法 |
| US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
| EP1667646A4 (en) * | 2003-09-26 | 2007-07-04 | David R Whitlock | METHOD FOR USE OF AMMONIA-OXIDATING BACTERIA |
| CN101028229B (zh) * | 2006-03-02 | 2012-09-05 | 北京富丽华德生物医药科技有限公司 | 基于一氧化氮的新型化妆品 |
| EE05341B1 (et) * | 2008-05-13 | 2010-08-16 | O� Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek |
| CA2728789A1 (en) * | 2008-06-24 | 2009-12-30 | Micropharma Limited | Nitric oxide compositions and devices and methods for cosmesis |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US8668937B2 (en) | 2011-03-17 | 2014-03-11 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
| CA2835320A1 (en) | 2011-05-09 | 2012-11-15 | Topical Therapeutic Agent (Tta) Ltd. | Nitric oxide-sequestering topical formulations |
| US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
| US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
| US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
| US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
| US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
| US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
| US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
| US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
| US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US10471109B2 (en) | 2013-05-04 | 2019-11-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for promoting nitric oxide production through an oral delivery system |
| US9974311B2 (en) * | 2013-09-23 | 2018-05-22 | Stewart Group Trading Inc. | Impregnated odour control products and methods of making the same |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| JP7088986B2 (ja) * | 2014-04-15 | 2022-06-21 | エーオーバイオーム， エルエルシー． | アンモニア酸化Ｎｉｔｒｏｓｏｍｏｎａｓ ｅｕｔｒｏｐｈａ株Ｄ２３ |
| US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
| US20170037363A1 (en) | 2014-04-15 | 2017-02-09 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
| WO2015179669A1 (en) * | 2014-05-22 | 2015-11-26 | Aobiome Llc | Methods of preparing materials with ammonia oxidizing bacteria and testing materials for ammonia oxidizing bacteria |
| US10383900B2 (en) * | 2014-05-22 | 2019-08-20 | Aobiome Llc | Systems and methods for storage and delivery of ammonia oxidizing bacteria |
| WO2016090366A1 (en) * | 2014-12-05 | 2016-06-09 | Can Technologies, Inc. | Animal feed supplement and method |
| RU2684624C2 (ru) * | 2014-12-26 | 2019-04-10 | Колгейт-Палмолив Компани | Композиция для личной гигиены с фосфатом цинка в качестве активного вещества |
| EP3943160A1 (en) * | 2015-07-02 | 2022-01-26 | Aobiome LLC | Ammonia oxidizing bacteria for treatment of acne |
| US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
| US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
| US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
| US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| EP3436156A1 (en) | 2016-03-31 | 2019-02-06 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
| WO2018017583A1 (en) | 2016-07-19 | 2018-01-25 | Aobiome Llc | Ammonia oxidizing microorganisms for use and delivery to the gastrointestinal system |
| BR112019005536A2 (pt) | 2016-09-21 | 2019-06-25 | Aobiome Llc | microrganismos oxidantes de amônia para uso e entrega para o sistema intranasal |
| AU2017365019A1 (en) | 2016-11-23 | 2019-07-11 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| JP2020503286A (ja) | 2016-12-12 | 2020-01-30 | エーオーバイオーム， エルエルシー．ＡＯＢｉｏｍｅ， ＬＬＣ． | 血圧の調節のためのアンモニア酸化微生物 |
| EP3638274A1 (en) | 2017-06-13 | 2020-04-22 | Aobiome LLC | Ammonia oxidizing microorganisms for dispersing biofilms |
| EP3415595A1 (en) * | 2017-06-16 | 2018-12-19 | The Procter & Gamble Company | Surface treatment composition comprising microbial consortium for suppressing non-gras microorganisms on a surface |
| WO2019018424A1 (en) * | 2017-07-18 | 2019-01-24 | Aobiome Llc | MICROORGANISMS OXIDIZING AMMONIA FOR USE AND ADMINISTRATION TO THE VISUAL AND AUDITIVE SYSTEMS |
| EP3654998A4 (en) * | 2017-07-18 | 2021-04-21 | Aobiome LLC | MICRO-ORGANISMS FOR USE AND PROVISION TO THE RESPIRATORY SYSTEM |
| EP3675883A4 (en) * | 2017-08-30 | 2021-05-12 | Aobiome LLC | MICROORGANISMS OXIDIZING AMMONIA FOR THE TREATMENT OF BUTTERFLY ERYTHEMA, ATHLETE'S FOOT, CONTACT DERMATITIS, SWEAT AND BODY ODORS |
| WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
| WO2019114705A1 (zh) | 2017-12-13 | 2019-06-20 | 上海小午医药科技有限公司 | 一种用于预防或治疗与egfr被抑制相关疾病的方法 |
| WO2019126711A1 (en) * | 2017-12-22 | 2019-06-27 | Aobiome Llc | Veterinary use and delivery of ammonia oxidizing microorganisms |
| CN114028568A (zh) | 2018-04-16 | 2022-02-11 | 上海岸阔医药科技有限公司 | 预防或治疗肿瘤疗法副作用的方法 |
| CN113003723B (zh) * | 2021-02-08 | 2022-05-17 | 清华大学 | 一种耦合菌群生物膜的制备方法 |
| WO2024189071A1 (en) | 2023-03-13 | 2024-09-19 | Universität Wien | Skin archaea preparation |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3984575A (en) | 1974-02-06 | 1976-10-05 | Microlife Technics, Inc. | Bacterial compositions for changing the digestive system bacteria in animals |
| US4147807A (en) | 1977-09-06 | 1979-04-03 | Microlife Technics, Inc. | Process for the treatment of meat with compositions including Micrococcus varians and a lactic acid producing bacteria |
| US4335107A (en) | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella |
| FI59925C (fi) | 1980-01-11 | 1981-11-10 | Esko Viljo Nurmi | Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae |
| JPS59135845A (ja) | 1983-01-25 | 1984-08-04 | Sohei Sawamura | 有効土壌菌を含む飼料用添加原剤 |
| US4720344A (en) | 1985-04-18 | 1988-01-19 | Ganczarczyk Jerzy J | Nitrification process in waste water treatment |
| IT1227154B (it) | 1988-08-05 | 1991-03-19 | A Tosi Farmaceutici S R L Nova | Composizioni farmaceutiche per uso ginecologico a base di lattobacilli |
| JPH02121665A (ja) * | 1988-11-01 | 1990-05-09 | Mitsubishi Mining & Cement Co Ltd | 紙オムツ |
| JPH0688028B2 (ja) | 1988-12-21 | 1994-11-09 | 三菱マテリアル株式会社 | 速効性尿石溶解剤 |
| SE465206B (sv) | 1989-12-22 | 1991-08-12 | Eva Grahn | Farmaceutisk beredning foer bekaempning av patogena tarmbakterier |
| JPH03289957A (ja) * | 1990-03-06 | 1991-12-19 | Daio Paper Corp | 紙おむつ |
| US5139792A (en) | 1990-07-19 | 1992-08-18 | Bio-Techniques Laboratories, Inc. | Method and system for dispensing live bacteria into animal feed and drinking water |
| DE69133584D1 (de) | 1990-12-05 | 2007-12-13 | Gen Hospital Corp | Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma |
| US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
| US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
| DE69332087T2 (de) | 1992-02-07 | 2002-10-24 | Etobicocke Vasogen Inc. | Verfahren zur erhöhung den stickoxidkonzentration im blut |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5646181A (en) | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
| US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US5340577A (en) | 1992-07-29 | 1994-08-23 | The United States Of America, As Represented By The Secretary Of Agriculture | Probiotic for control of salmonella |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5385940A (en) | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| BR9405999A (pt) | 1993-03-16 | 1995-12-19 | Us Agriculture | Flora de exclusão competitiva relativa à mucosa |
| US5427797A (en) | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
| GB2279014B (en) | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
| US5861168A (en) | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| US5314542A (en) * | 1993-08-06 | 1994-05-24 | Precision Aquarium Testing, Inc. | Nitrosomonas preservation and reactivation for aquaria |
| US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
| GB9320978D0 (en) | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
| DK0726768T3 (da) | 1993-11-02 | 2000-10-02 | Us Health | Anvendelse af nitrogenoxidfrigørende forbindelser til fremstillingen af et medikament til beskyttelse i iskæmisk reperfusio |
| US5470847A (en) | 1993-12-10 | 1995-11-28 | Board Of Regents, The University Of Texas System | Ovulation control by regulating nitric oxide levels with arginine derivatives |
| AU2282395A (en) | 1994-05-27 | 1995-12-21 | Neptune Pharmaceutical Corporation | Nitric oxide donor composition and method for treatment of anal disorders |
| US5543430A (en) | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
| US5519020A (en) | 1994-10-28 | 1996-05-21 | The University Of Akron | Polymeric wound healing accelerators |
| US5648101A (en) | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
| EP0799051B1 (en) | 1994-12-12 | 2005-07-27 | Omeros Corporation | Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| US6063407A (en) | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US5595753A (en) | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
| US5665077A (en) | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US5534253A (en) | 1995-06-07 | 1996-07-09 | Biogaia Ab | Method of treating enteropathogenic bacterial infections in poultry |
| US5900433A (en) | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| JP3252888B2 (ja) * | 1995-09-11 | 2002-02-04 | 日立プラント建設株式会社 | 生物学的窒素除去装置 |
| US5876603A (en) * | 1995-08-10 | 1999-03-02 | Hitachi Plant Engineering & Construction Co., Ltd. | Method of biologically removing nitrogen and system therefor |
| EP0780419A1 (en) * | 1995-12-22 | 1997-06-25 | Holland Biomaterials Group B.V. | Multi-functional site containing polymers, and applications thereof |
| US5849192A (en) | 1996-02-12 | 1998-12-15 | Basf Corporation | Procedure to recover from nitrification upsets |
| US5725492A (en) | 1996-03-04 | 1998-03-10 | Cormedics Corp | Extracorporeal circulation apparatus and method |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| US5765548A (en) | 1996-05-07 | 1998-06-16 | Perry; Bryan J. | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine |
| US5821112A (en) | 1996-10-04 | 1998-10-13 | Botto; Willism S. | Biological odor metabolizing compositions and methods of use |
| US5807546A (en) | 1996-10-11 | 1998-09-15 | The United States Of America As Represented By The Secretary Of Agriculture | Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria |
| US5958427A (en) | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
| US5891472A (en) | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
| FR2764802A1 (fr) | 1996-12-24 | 1998-12-24 | Standa Lab Sa | Composition adsorbable renfermant des bacteries propioniques susceptible de degager du monoxyde d'azote dans le tube digestif humain ou animal |
| US20050036996A1 (en) * | 1996-12-24 | 2005-02-17 | Edmond Roussel | Absorbable composition containing propionic bacteria capable of releasing nitric oxide in the human or animal alimentary canal |
| US5912019A (en) | 1997-02-07 | 1999-06-15 | Musc Foundation For Research Development | Compounds for reducing ischemia/reperfusion injury |
| US5895658A (en) | 1997-09-17 | 1999-04-20 | Fossel; Eric T. | Topical delivery of L-arginine to cause tissue warming |
| US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
| CA2243011C (en) * | 1998-07-13 | 2007-02-13 | Life Science Technology Group, Inc. | Odor control agent for carpet and the like and method of use thereof |
| CN1308438C (zh) | 2002-01-11 | 2007-04-04 | 大卫·R·怀特洛克 | 含有氨氧化细菌的化合物以及使用的方法 |
| EP1667646A4 (en) | 2003-09-26 | 2007-07-04 | David R Whitlock | METHOD FOR USE OF AMMONIA-OXIDATING BACTERIA |
-
2001
- 2001-08-10 EA EA200300253A patent/EA005649B1/ru not_active IP Right Cessation
- 2001-08-10 AU AU2001284849A patent/AU2001284849B2/en not_active Expired
- 2001-08-10 DE DE60136366T patent/DE60136366D1/de not_active Expired - Lifetime
- 2001-08-10 CA CA2414941A patent/CA2414941C/en not_active Expired - Lifetime
- 2001-08-10 CN CNB018137946A patent/CN1267212C/zh not_active Expired - Lifetime
- 2001-08-10 OA OA1200300041A patent/OA12585A/en unknown
- 2001-08-10 WO PCT/US2001/025248 patent/WO2002013982A1/en active Application Filing
- 2001-08-10 AT AT01963935T patent/ATE412475T1/de not_active IP Right Cessation
- 2001-08-10 KR KR10-2003-7001998A patent/KR20030065463A/ko not_active Application Discontinuation
- 2001-08-10 IL IL15395601A patent/IL153956A0/xx unknown
- 2001-08-10 AP APAP/P/2003/002721A patent/AP1682A/en active
- 2001-08-10 EP EP01963935A patent/EP1313574B1/en not_active Expired - Lifetime
- 2001-08-10 BR BRPI0113085-4A patent/BRPI0113085B1/pt not_active IP Right Cessation
- 2001-08-10 US US10/332,933 patent/US7820420B2/en not_active Expired - Fee Related
- 2001-08-10 JP JP2002519111A patent/JP2004506028A/ja active Pending
- 2001-08-10 AU AU8484901A patent/AU8484901A/xx active Pending
- 2001-08-10 MX MXPA03001280A patent/MXPA03001280A/es active IP Right Grant
-
2003
- 2003-01-14 IL IL153956A patent/IL153956A/en active IP Right Grant
- 2003-01-14 ZA ZA200300377A patent/ZA200300377B/en unknown
-
2010
- 2010-09-24 US US12/889,936 patent/US8388989B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030065463A (ko) | 2003-08-06 |
| ATE412475T1 (de) | 2008-11-15 |
| AP2003002721A0 (en) | 2003-06-30 |
| US20110232650A1 (en) | 2011-09-29 |
| US20040014188A1 (en) | 2004-01-22 |
| IL153956A (en) | 2012-01-31 |
| AU2001284849B2 (en) | 2006-11-30 |
| US7820420B2 (en) | 2010-10-26 |
| EP1313574A1 (en) | 2003-05-28 |
| WO2002013982A1 (en) | 2002-02-21 |
| BRPI0113085B1 (pt) | 2017-09-19 |
| CA2414941C (en) | 2010-12-14 |
| AU8484901A (en) | 2002-02-25 |
| EA005649B1 (ru) | 2005-04-28 |
| CA2414941A1 (en) | 2002-02-21 |
| AP1682A (en) | 2006-11-27 |
| CN1267212C (zh) | 2006-08-02 |
| US8388989B2 (en) | 2013-03-05 |
| BRPI0113085B8 (el) | 2021-05-25 |
| CN1446128A (zh) | 2003-10-01 |
| JP2004506028A (ja) | 2004-02-26 |
| BR0113085A (pt) | 2003-07-22 |
| DE60136366D1 (de) | 2008-12-11 |
| EA200300253A1 (ru) | 2003-08-28 |
| EP1313574B1 (en) | 2008-10-29 |
| EP1313574A4 (en) | 2004-09-22 |
| OA12585A (en) | 2006-06-07 |
| MXPA03001280A (es) | 2004-07-30 |
| IL153956A0 (en) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7820420B2 (en) | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same | |
| US20050106126A1 (en) | Compositions including ammonia oxidizing bacteria and methods of using same | |
| AU2001284849A1 (en) | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same | |
| CN107429213A (zh) | 储存和递送氨氧化细菌的系统和方法 | |
| CN106471129A (zh) | 用氨氧化细菌制备材料和测试材料的氨氧化细菌的方法 | |
| CN110191716A (zh) | 用于鼻内系统使用和递送至鼻内系统的氨氧化微生物 | |
| US20240189368A1 (en) | Ammonia oxidizing microorganisms for dispersing biofilms | |
| CN108367029A (zh) | 用于治疗痤疮的氨氧化细菌 | |
| US20240293477A1 (en) | Ammonia oxidizing microorganisms for the treatment of diaper rash, athlete’s foot, contact dermatitis, perspiration, and body odor | |
| ES2332411T3 (es) | Nuevo lactobacillus, preparacion de lactobacillus que activa un organismo vivo y agente preventivo o terapeutico contra la infeccion de un organismo vivo. | |
| CN104399017A (zh) | 一种防治女性外阴炎症的组合物 | |
| KR20030037243A (ko) | 바이오 신물질 소재를 이용한 섬유소재와 그 제조방법 | |
| BR122015019488B1 (pt) | Non-therapeutic cosmetic nitric oxide supply method for a individual understanding the application of ammonia oxiding bacteria | |
| US20230404905A1 (en) | Ammonia oxidizing microorganisms for ph modulation | |
| KR20020038640A (ko) | 목초액을 이용한 발모제 | |
| CN106668849A (zh) | 一种预防及治疗人体异味的组合物试剂盒及其使用方法 |